Use of a HIV derived accessory protein for the reactivation of latent HIV
View Patent ↗The present invention concerns the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells present in a HIV-infected patient.
1. A method of reversing HIV-1 latency in an HIV infected cell, comprising exposing the HIV infected cell to a mutant protein of an HIV Tat which consists of the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.
2. A method of reversing HIV-1 latency in an HIV infected cell, comprising exposing the HIV infected cell to a fusion protein which consists of mutant protein fused to a transactivation domain, wherein the mutant protein consists of either SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; and wherein the transactivation domain consists of the transactivation domain of either NFκB p65 or NFAT2.
3. The method of claim 1 , wherein said amino acid sequence is SEQ ID NO:1.
4. The method of claim 1 , wherein said amino acid sequence is SEQ ID NO:2.
5. The method of claim 1 , wherein said amino acid sequence is SEQ ID NO:3.
6. The method of claim 2 , wherein said mutant protein consists of SEQ ID NO:1.
7. The method of claim 6 , wherein said transactivation domain is the transactivation domain of NFκB p65.
8. The method of claim 6 , wherein said transactivation domain is the transactivation domain of NFAT2.
9. The method of claim 2 , wherein said mutant protein consists of SEQ ID NO:2.
10. The method of claim 9 , wherein said transactivation domain is the transactivation domain of NFκB p65.
11. The method of claim 9 , wherein said transactivation domain is the transactivation domain of NFAT2.
12. The method of claim 2 , wherein said mutant protein consists of SEQ ID NO:3.
13. The method of claim 12 , wherein said transactivation domain is the transactivation domain of NFκB p65.
14. The method of claim 12 , wherein said transactivation domain is the transactivation domain of NFAT2.